TY - JOUR
T1 - The Nedd8-Activating enzyme inhibitor MLN4924 thwarts microenvironment- driven NF-kB activation and induces apoptosis in chronic lymphocytic leukemia B cells
AU - Godbersen, J. Claire
AU - Humphries, Leigh Ann
AU - Danilova, Olga V.
AU - Kebbekus, Peter E.
AU - Brown, Jennifer R.
AU - Eastman, Alan
AU - Danilov, Alexey V.
PY - 2014
Y1 - 2014
N2 - Background: Stromal-mediated signaling enhances NF-kB pathway activity in chronic lymphocytic leukemia (CLL) B cells, leading to cell survival and chemoresistance. Ubiquitination of IkBa may partially account for constitutive activation of NF-kB. MLN4924 is an investigational agent that inhibits the Nedd8- activating enzyme, thereby neutralizing Cullin-RING ubiquitin ligases and preventing degradation of their substrates. Experimental Design: We conducted a preclinical assessment of MLN4924 in CLL. Primary CLL cells were cocultured in vitro with CD40L-expressing stroma to mimic the prosurvival conditions present in lymphoid tissue. The effect of MLN4924 on CLL cell apoptosis, NF-kB pathway activity, Bcl-2 family members, and cell cycle was assessed by flow cytometry, Western blotting, PCR, and immunocytochemistry. Results: CD40L-expressing stroma protected CLL cells from spontaneous apoptosis and induced resistance to multiple drugs, accompanied by NF-kB activation and Bim repression. Treatment with MLN4924 induced CLL cell apoptosis and circumvented stroma-mediated resistance. This was accompanied by accumulation of phospho-IkBa, decreased nuclear translocation of p65 and p52 leading to inhibition of both the canonical and noncanonical NF-kB pathways, and reduced transcription of their target genes, notably chemokines. MLN4924 promoted induction of Bim and Noxa in the CLL cells leading to rebalancing of Bcl-2 family members toward the proapoptotic BH3-only proteins. siRNA-mediated knockdown of Bim or Noxa decreased sensitivity to MLN4924. MLN4924 enhanced the antitumor activity of the inhibitors of B-cell receptor (BCR)-Associated kinases. Conclusions: MLN4924 disrupts NF-kB activation and induces Bim expression in CLL cells, thereby preventing stroma-mediated resistance. Our data provide rationale for further evaluation of MLN4924 in CLL.
AB - Background: Stromal-mediated signaling enhances NF-kB pathway activity in chronic lymphocytic leukemia (CLL) B cells, leading to cell survival and chemoresistance. Ubiquitination of IkBa may partially account for constitutive activation of NF-kB. MLN4924 is an investigational agent that inhibits the Nedd8- activating enzyme, thereby neutralizing Cullin-RING ubiquitin ligases and preventing degradation of their substrates. Experimental Design: We conducted a preclinical assessment of MLN4924 in CLL. Primary CLL cells were cocultured in vitro with CD40L-expressing stroma to mimic the prosurvival conditions present in lymphoid tissue. The effect of MLN4924 on CLL cell apoptosis, NF-kB pathway activity, Bcl-2 family members, and cell cycle was assessed by flow cytometry, Western blotting, PCR, and immunocytochemistry. Results: CD40L-expressing stroma protected CLL cells from spontaneous apoptosis and induced resistance to multiple drugs, accompanied by NF-kB activation and Bim repression. Treatment with MLN4924 induced CLL cell apoptosis and circumvented stroma-mediated resistance. This was accompanied by accumulation of phospho-IkBa, decreased nuclear translocation of p65 and p52 leading to inhibition of both the canonical and noncanonical NF-kB pathways, and reduced transcription of their target genes, notably chemokines. MLN4924 promoted induction of Bim and Noxa in the CLL cells leading to rebalancing of Bcl-2 family members toward the proapoptotic BH3-only proteins. siRNA-mediated knockdown of Bim or Noxa decreased sensitivity to MLN4924. MLN4924 enhanced the antitumor activity of the inhibitors of B-cell receptor (BCR)-Associated kinases. Conclusions: MLN4924 disrupts NF-kB activation and induces Bim expression in CLL cells, thereby preventing stroma-mediated resistance. Our data provide rationale for further evaluation of MLN4924 in CLL.
UR - http://www.scopus.com/inward/record.url?scp=84896515296&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896515296&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-13-0987
DO - 10.1158/1078-0432.CCR-13-0987
M3 - Article
C2 - 24634471
AN - SCOPUS:84896515296
SN - 1078-0432
VL - 20
SP - 1576
EP - 1589
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 6
ER -